68Ga-PSMA PET/CT

DIAGNOSTIC_TEST3 trials

Sponsors

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, University of Saskatchewan, Xiangya Hospital of Central South University

Conditions

68Ga-PSMA PET/CT Guided Prostate BiopsyDiagnosisMp-3TMRI Guided Prostate BiopsyProstate CancerTNM Staging

Phase 3

68Ga-PSMA PET/CT in Prostate Cancer

SuspendedNCT04684628

University of SaskatchewanProstate Cancer

Start: 2020-12-09End: 2025-12-31Target: 500Updated: 2024-05-02

Unknown Phase

Mp-3TMRI and 68Ga-PSMA PET/CT Guided Prostate Biopsy and Tumor Node Metastasis (TNM) Staging.

TerminatedNCT03465579

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS68Ga-PSMA PET/CT Guided Prostate Biopsy, Diagnosis, Mp-3TMRI Guided Prostate Biopsy +2

Start: 2018-05-23End: 2024-09-03Updated: 2025-01-30

A Study of 68Ga-GRP PET/CT for Imaging in Low and Intermediate Risk Prostate Cancer

Xiangya Hospital of Central South UniversityProstate Cancer

Start: 2021-10-11End: 2022-12-31Target: 80Updated: 2021-10-19

Related Papers

Dual-tracer PET/CT with [<sup>68</sup>Ga]Ga-PSMA-617 and [<sup>68</sup>Ga]Ga-RM26 improves early prediction of biochemical failure in prostate cancer: a prospective phase II trial.

2025-10-03

Which patients with negative PSMA-PET imaging can safely avoid biopsy for prostate cancer? a novel step towards PSMA-based biopsy-free strategy.

2025-01-251 citations